Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2

NCT04575038 is registered in ClinicalTrials.gov with Clear Creek Bio, Inc. as lead sponsor.

NCT NCT04575038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04575038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2
Lead sponsor
Clear Creek Bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2020
Completion date
April 28, 2021
Enrollment
115 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection